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Abstract
Follicular Dendritic cell sarcoma arises from the 
follicular dendritic cells present in the lymphnode. 
Though is commonly seen in the head and neck area 
but is extremely rare in the abdomen. Less than eighty 
cases are reported in the indexed literature. We herein 
describe a case of follicular dendritic cell sarcoma 
arising from the stomach wall with infiltration into the 
pancreas in an 85 year old patient.
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INTRODUCTION
Follicular Dendritic Cell Sarcoma is a rare neoplasm, 
arises from the follicular dendritic cell of the germinal 
center. Follicular dendritic cells are mesenchymal in 
origin and are involved in Humoral Immunity. These cells 
express CD 21, CD23, CD 35. These can arise from both 
nodal and extranodal site[1]. FDCS cases reported in the 
english literature are extreemly rare and less than eighty 
in number[2-5]. The involvement of GIT is extremely rare. 
To our knowledge, only few cases have been described 
to date and these were located mostly in the colon 
and retroperitoneum[6-7]. Upon review of literature, we 
identified only three additional cases of FDCS presenting 
as primary stomach tumour[8]. To add to the existing 
literature, we present a case of follicular dendritic cell 
sarcoma of stomach infiltrating into pancreas.
CASE REPORT
An 85-year-old male with no co morbidities presented 
with loss of appetite, and early satiety for three months. 
He had intermittent abdominal pain for two months. 
Vomiting, altered bowel habits and melaena were absent. 
A well-defined 14 cm ×10 cm mass involving the left 
hypochondriac, lumbar, and umbilical areas was found. 
There were no ascites or palpable neck nodes. 
Ultrasonography revealed a solid mass of 15×13 
cm with cystic component in the centre with increased 
vascularity. CT scan (Figure 1) showed mass lesion with 
large necrotic area, appearing to arise from the posterior 
wall of stomach with retroperitoneal extension. The lesion 
was PET avid. EUS guided FNAC was suggestive of 
either low grade neuroendocrine carcinoma or epitheloid 
Gastro-intestinal stromal tumour (GIST). Serum 
chromogranin was 372ng/ml. Routine blood investigations 
were within normal range.
Figure 1 
CECT Abdomen
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In view of the possibility of GIST being real, he 
was put on Imatinib Mesylate trial for two weeks. 
Patient had generalised serositis including pericardial 
effusion. Reassessment with PET-CT showed no 
response. 
The  pa t ien t  underwent  surg ica l  explora t ion 
(Figure 2a, 2b) with en-bloc resection of the tumour 
with wedge gastrectomy with distal pancreatico-
splenectomy.
Figure 2a 
Tumour Insitu Arising From Stomach Posteriorly 
Along the Lesser Curvature (White Arrow) With 
Infiltration Into The Body and Tail Of Pancreas (Black 
Arrow-Thin). Splenic Vein Was Pushed Inferiorly 
(Black Arrow- Thick)
Figure 2b
Enbloc Resected Specimen
On gross examination it was an 18×14 cm solid 
mass arising from the posterior wall of stomach with 
infiltration into body and tail of pancreas weighing 2.2 
kgs. Histopathological examination (Figure 3) showed 
spindle shaped cells with a few scattered severed small 
lymphocytes. There were three mitoses /10 hpf. Tumour 
cells showed marked pleomorphism. Histopathological 
examination was suspicious of follicular dendritic cell 
sarcoma.
Figure 3 
H a e m a t o x i l i n  a n d  E o s i n  S t a i n e d  ( 1 0 X ) 
photomicrograph Showing a Well Formed Capsule 
and Tumour Cells
On Immunohistochemistry, the tumour cells expressed 
CD21, CD23, and CD35 (Figures 4, 5 and 6). It was 
immunonegative for CD117, CD34, DOG1, Desmin, 
SMA. Thus the diagnosis of follicular dendritic cell 
sarcoma was confirmed. No adjuvant therapy was 
recommended. Follow up CECT abdomen at six weeks 
and 6 months revealed no recurrence.
Figure 4 
Photomicrograph (4X) Showing a Positive CD 21 
Immunoreaction With Capsule and Normal Stomach 
Interface
Figure 5
 Photomicrograph (4X) Showing a Positive CD23 
Immunoreactivity by Tumour Cells 
3 Copyright © Canadian Research & Development Center of Sciences and Cultures
S. Nikhil, P. J. Halder, S. Swapnil, R. Santhosh (2015). 
Gastroenterology and Hepatology, 2(1), 1-4
Figure 6  
Photomicrograph (4X) Showing a Positive CD 35 
Immunoreactivity by Tumour Cells
DISCUSSION
The available indexed English literature search was made 
in pubmed, directory of open access journals (DOAJ) and 
google search till date. Mesh terms “Follicular dendritic 
cell sarcoma”, “extranodal fdcs” were used. The relevant 
literature is reviewed.
FDCS is a rare tumor of dendritic-histiocytic cell 
origin, less than 80 cases have been reported in the 
English literature[2-5]. Monda et al. first described FDCS 
in 1986 and Chan et al reported the first extranodal tumor 
in 1994[9-11].  Since then the tumor has been reported in 
various sites like palate, tonsils, stomach, mesocolon, 
pancreas, breast, small intestine [1-2,6]. Wang et al found 
that more than half of the reported cases fall in extranodal 
group. This neoplasm affects both sexes equally, and 
the disease occurs over a wide age range from 14 to 77 
years (mean age: 47 years). The disease typically presents 
as a painless, slow growing, well-defined mass lesion 
at the involved site[12]. The causes of FDCS are largely  
unknown. Associations with Castleman disease[13] and 
Ebstein-Barr virus[14] have been reported. In addition, 
relationships  have been found with autoimmune disease 
such as paraneoplastic pemphigus[8] and myasthenia 
gravis[8]. The diagnosis was challenging as the neoplasm 
appeared consistent to be gastrointestinal stromal tumour 
based on morphology and histopathological examination. 
To our surprise, finally it turned out to be a FDCS, after 
the detailed immunohistochemistry markers were studied. 
Immunohistochemical study in our case was helpful as 
FDCS is consistently negative for CD34, CD117 (positive 
in GIST), S-100 (positive in Melanoma and interdigitating 
reticulum cell  tumors),  cytokeratin (posit ive in 
sarcomatoid carcinoma), sma (positive in smooth muscle 
tumors). CD21, CD23, CD 35 markers were positive. 
The tumor is considered to be a low grade neoplasm 
with a tendency to recur. More aggressive behavior has 
been noted by some, when the tumor is found in the intra-
abdominal location [15]. Podoplanin, clusterin, fascin are 
the recently empoyed markers apart from CD21, CD23, 
CD35[16-17]. The behavior of these tumors is more akin to 
that of a low-grade soft tissue sarcoma than a malignant 
lymphoma, and is characterized by local recurrence in 
36% of cases and metastases in 28%[18]
Complete surgical resection is the treatment of choice 
whenever feasible. 
There are no consensus on optimal chemotherapy and 
adjuvant therapy[19]. The CHOP  (cyclophosphamide–
hydroxydaunorubicin–vincrist ine–prednisolone) 
chemotherapy regimen is perhaps the most widely used 
regimen[20]. Polyethylene glycol liposomal doxorubicin 
has also been used, with a fauvorable response[21]. 
Adjuvant radiotherapy or chemotherapy appears to be 
indicated in cases having adverse pathological features 
and in recurrent or incompletely resected lesions. Cases 
with microscopic features such as significant cytological 
atypia, extensive coagulative necrosis, high proliferative 
index (mitotic count of >5/10 hpf), or tumor size greater 
than 6 cm have poor prognosis, whereas lesions arising 
in the lymph nodes behave as low-grade sarcoma with a 
relatively good prognosis[16]
Naturally FDCS did not respond to imatinib trial since 
they don’t express CD 117, as is evident in our case. 
CD 117 and CD 34 are negative in less than 5% of cases 
diagnosed as GIST [22]. A differential of FDCS seems 
logical in such scenario.
CONCLUSION
Follicular dendritic cell sarcoma should be considered 
as a differential diagnosis in cases of CD34 and CD117 
negativity in a spindle cell tumour of gastrointestinal tract. 
Surgical resection is preferred choice of treatment. Further 
research into adjuvant therapy may improve the outcomes 
and survival.
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